Deacon CF, Mannucci E, Ahrén B (August 2012). "Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis". Diabetes Obes Metab. 14 (8): 762–7. doi:10.1111/j.1463-1326.2012.01603.x. PMID22471248. S2CID21833823.
Kingston W (July 2004). "Streptomycin, Schatz v. Waksman, and the balance of credit for discovery". J Hist Med Allied Sci. 59 (3): 441–62. doi:10.1093/jhmas/jrh091. PMID15270337. S2CID27465970.
Vaithianathan R, Hockey PM, Moore TJ, Bates DW (2009). "Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey". Drug Saf. 32 (4): 335–43. doi:10.2165/00002018-200932040-00007. PMID19388724. S2CID41806262.
Eriksen EF, Díez-Pérez A, Boonen S (January 2014). "Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review". Bone. 58: 126–35. doi:10.1016/j.bone.2013.09.023. PMID24120384.
Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G (December 2013). "Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis". Gynecol. Endocrinol. 29 (12): 1005–14. doi:10.3109/09513590.2013.813468. PMID24063695. S2CID20163452.
Deacon CF, Mannucci E, Ahrén B (August 2012). "Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis". Diabetes Obes Metab. 14 (8): 762–7. doi:10.1111/j.1463-1326.2012.01603.x. PMID22471248. S2CID21833823.
Kingston W (July 2004). "Streptomycin, Schatz v. Waksman, and the balance of credit for discovery". J Hist Med Allied Sci. 59 (3): 441–62. doi:10.1093/jhmas/jrh091. PMID15270337. S2CID27465970.
Vaithianathan R, Hockey PM, Moore TJ, Bates DW (2009). "Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey". Drug Saf. 32 (4): 335–43. doi:10.2165/00002018-200932040-00007. PMID19388724. S2CID41806262.
Eriksen EF, Díez-Pérez A, Boonen S (January 2014). "Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review". Bone. 58: 126–35. doi:10.1016/j.bone.2013.09.023. PMID24120384.
Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G (December 2013). "Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis". Gynecol. Endocrinol. 29 (12): 1005–14. doi:10.3109/09513590.2013.813468. PMID24063695. S2CID20163452.
Gauthier K, Bai A, Perras C, et al. (2012). "Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms [Internet]". PMID24278999. {{cite journal}}: Cite journal requires |journal= (help)
Deacon CF, Mannucci E, Ahrén B (August 2012). "Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis". Diabetes Obes Metab. 14 (8): 762–7. doi:10.1111/j.1463-1326.2012.01603.x. PMID22471248. S2CID21833823.
Kingston W (July 2004). "Streptomycin, Schatz v. Waksman, and the balance of credit for discovery". J Hist Med Allied Sci. 59 (3): 441–62. doi:10.1093/jhmas/jrh091. PMID15270337. S2CID27465970.
Vaithianathan R, Hockey PM, Moore TJ, Bates DW (2009). "Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey". Drug Saf. 32 (4): 335–43. doi:10.2165/00002018-200932040-00007. PMID19388724. S2CID41806262.
Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G (December 2013). "Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis". Gynecol. Endocrinol. 29 (12): 1005–14. doi:10.3109/09513590.2013.813468. PMID24063695. S2CID20163452.